Search Results

A role for ceftazidime/avibactam combination therapy: the question may still be on the table.

• Authors : Volpicelli L; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.; Oliva A

• Source: Infection [Infection] 2024 Jul 04. Date of Electronic Publication: 2024 Jul 04.Publisher: Springer Heidelberg Country of Publication: Germany NLM ID: 0365307 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience.

• Authors : Leanza C; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.; Mascellino MT

• Source: Frontiers in microbiology [Front Microbiol] 2024 Jul 16; Vol. 15, pp. 1432296. Date of Electronic Publication: 2024 Jul 16 (Print Publication: 2024).Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101548977 Publication Model: eCollection Cited Medium: Print

Record details

Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin.

• Authors : Volpicelli L; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.; Cairoli S

Subjects: Fosfomycin*/Fosfomycin*/Fosfomycin*/therapeutic use ; Fosfomycin*/Fosfomycin*/Fosfomycin*/administration & dosage ; Anti-Bacterial Agents*/Anti-Bacterial Agents*/Anti-Bacterial Agents*/administration & dosage

• Source: Journal of global antimicrobial resistance [J Glob Antimicrob Resist] 2024 Jun; Vol. 37, pp. 86-90. Date of Electronic Publication: 2024 Mar 20.Publisher: Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer Country of Publication: Netherlands NLM ID:

Record details

New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.

• Authors : Oliva A; Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.; Cogliati Dezza F

• Source: Journal of clinical medicine [J Clin Med] 2023 Dec 14; Vol. 12 (24). Date of Electronic Publication: 2023 Dec 14.Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383

Record details

Did the updated Duke criteria missed Erysipelothrix rhusiopathiae from the list of typical microorganisms causing infective endocarditis?

• Authors : Volpicelli L; Department of Public Health and Infectious Disease, Sapienza University of Rome, Italy.; Oliva A

• Source: Le infezioni in medicina [Infez Med] 2023 Dec 01; Vol. 31 (4), pp. 425-428. Date of Electronic Publication: 2023 Dec 01 (Print Publication: 2023).Publisher: Edizioni Internazionali srl Country of Publication: Italy NLM ID: 9613961 Publication Model: eCollection Cited Medium: Internet ISSN:

Record details

Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study.

• Authors : Oliva, A.; Volpicelli, L.; Di Bari, S.

• Source: JAC-Antimicrobial Resistance; Dec2022, Vol. 4 Issue 6, p1-11, 11p

Record details

Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations

• Authors : Oliva, A.; Al Ismail, D.; Arcari, G.

• Source: Journal of Global Antimicrobial Resistance; June 2023, Vol. 33 Issue: 1 p321-327, 7p

Record details

Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Klebsiella pneumoniae Infections: A Retrospective, Observational, 2-Center Clinical Study.

• Authors : Oliva A; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.; Campogiani L

• Source: Open forum infectious diseases [Open Forum Infect Dis] 2023 Jun 30; Vol. 10 (7), pp. ofad327. Date of Electronic Publication: 2023 Jun 30 (Print Publication: 2023).Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045

Record details

Evaluation of the Factors Associated with Reinfections towards SARS-CoV-2 Using a Case Control Design.

• Authors : La Torre G; Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.; Paglione G

• Source: Journal of clinical medicine [J Clin Med] 2023 Jun 05; Vol. 12 (11). Date of Electronic Publication: 2023 Jun 05.Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383

Record details

Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin.

• Authors : Volpicelli L; Department of Public Health and Infectious Diseases, Sapienza University of Rome Roma, Italy.; Venditti M

Subjects: Skin Diseases, Bacterial*/Skin Diseases, Bacterial*/Skin Diseases, Bacterial*/drug therapy ; Skin Diseases, Bacterial*/Skin Diseases, Bacterial*/Skin Diseases, Bacterial*/microbiology ; Soft Tissue Infections*/Soft Tissue Infections*/Soft Tissue Infections*/drug therapy

• Source: Expert review of anti-infective therapy [Expert Rev Anti Infect Ther] 2023 Apr; Vol. 21 (4), pp. 329-341. Date of Electronic Publication: 2023 Feb 27.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101181284 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details